This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ESMO 2022
ESMO 2022
Prostate Cancer
Bladder Cancer
Testicular and Penile Cancer
Press Releases
Kidney Cancer
ESMO 2022 Bladder Cancer
Viewing 1-16 of 16 articles
ESMO 2022: Latest Imaging Advances in PET and Beyond Translated to Bladder and Kidney Cancers
ESMO 2022: Invited Discussant: The Phase III VESPER Trial & the Phase III CheckMate 274 Trial
ESMO 2022: Pure or Mixed Basal/squamous Tumours Present Decreased Outcomes After Neoadjuvant Chemotherapy in the GETUG-AFU V05 VESPER Trial
ESMO 2022: Study EV-103 Cohort K: Antitumor Activity of Enfortumab Vedotin Monotherapy or in Combination with Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
ESMO 2022: Tumor and Immune Features Associated with Disease-Free Survival with Adjuvant Nivolumab in the Phase 3 CheckMate 274 Trial
ESMO 2022: Disease-Free Survival and Distant Metastasis-Free Survival as Surrogates for Overall Survival in Adjuvant Treatment of Muscle-Invasive Bladder Cancer
ESMO 2022: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results from Patients with ≥12 Months of Treatment in JAVELIN Bladder 100
ESMO 2022: Prevalence of PD-L1 High Expression in Advanced Urothelial Carcinoma (aUC): Results from the PREVAIL Prospective Cohort Study
ESMO 2022: Phase 2 Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin in Patients (pts) With HER2-Expressing Urothelial Carcinoma (RC48G001, Trial in Progress)
ESMO 2022: A Discussion on Radiation Therapy Before Radical Cystectomy combined with Immunotherapy in Locally Advanced Urothelial Carcinoma, First Results from BladderPath, and BC2001 and BCON Randomised Trials
ESMO 2022: First Results from BladderPath: A Randomised Trial of MRI Versus Cystoscopic Staging for Newly Diagnosed Bladder Cancer
ESMO 2022: RACE IT - A Prospective, Single Arm, Multicenter, Phase II-Trial to Assess Safety and Efficacy of Preoperative RAdiation Therapy Before Radical CystEctomy Combined with ImmunoTherapy in Locally Advanced Urothelial Carcinoma of the Bladder
ESMO 2022: Hypoxic Bladder Cancers Have a Poorer Outcome Following Hypofractionated Vs Conventionally Fractionated Radiotherapy in the BC2001 and BCON Randomised Trials
ESMO 2022: PD-L1 Expression on Immune Cells by SP142 Co-Localizes with Dendritic Cells and Is Associated with Improved OS with Atezolizumab in Patients with Untreated Metastatic Urothelial Cancer
ESMO 2022: Biomarkers for Advanced Urothelial Carcinoma: Are We There Yet?
ESMO 2022: Genomic Biomarkers in Peripheral Blood From Patients Enrolled in the JAVELIN Bladder 100 Trial of Avelumab First-line Maintenance in Advanced Urothelial Carcinoma
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free